Clinical features and treatment outcome of Epstein–Barr virus-positive nodal T-cell lymphoma

详细信息    查看全文

• 作者：Ki Sun Jung ; Su-Hee Cho ; Seok Jin Kim ; Young Hyeh Ko…
• 关键词：Epstein–Barr virus ; Mature NK ; /T ; cell lymphoma ; Survival ; Cyclophosphamide ; containing regimen
• 刊名：International Journal of Hematology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：104
• 期：5
• 页码：591-595
• 全文大小：492 KB
• 刊物主题：Hematology; Oncology;
• 出版者：Springer Japan
• ISSN：1865-3774
• 卷排序：104

文摘

The classification of mature NK-/T-cell lymphoma mainly originating from the T-cell lineage with predominantly nodal involvement and Epstein–Barr virus (EBV) positivity in a majority of tumor cells is unresolved. We analyzed the clinical features and treatment outcomes of such patients. Five patients with EBV-positive nodal T-cell lymphoma were surveyed during follow-up period. The median age was 53 years (range 33–88 years), and all patients showed nodal involvement. The patients mostly presented advanced clinical features, such as stage III or IV disease, elevated lactate dehydrogenase, and hemophagocytosis. Four patients received cyclophosphamide-containing chemotherapy at the time of diagnosis. However, three patients (75 %) showed disease progression during the early cycles of initial treatment. The median overall survival was 1.5 months (95 % CI 0.0–3.4 months). Patients with EBV-positive nodal T-cell lymphoma mainly show lymph node involvement, but also show aggressive clinical features and poor treatment outcomes, such as aggressive NK-cell leukemia. Therefore, we should consider EBV-positive nodal T-cell lymphoma to be a unique disease entity distinct from peripheral T-cell lymphoma not otherwise specified.